In recent years, KMT dysregulation has been associated with tumor development, metastasis, and chemoresistance, as well as the immune microenvironment, while KMT inhibitors are currently being applied in multiple preclinical and clinical trials and have shown promising results in a variety of malignancies [55]. The gene discussed is CAMKMT; the disease is neoplasm.